Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Key Takeaways from the ISPOR Europe 2022 Conference
Last month, Trinity attended the ISPOR Europe 2022 conference in Vienna. The main theme of the conference was “Collaborating Across Borders: Building & Using Evidence to Enable Access”, which facilitated many interesting discussions amongst different stakeholders in life sciences, including...
Blog
The Enhancing Oncology Care Model: Where Public Health Meets Oncology Care
Executive Summary Introduction The OCM has recently concluded after five years of existence. Institutional participants advocated for a follow-up model – and following numerous reviews and analyses of the successes and points of improvement of the OCM, Centers for Medicare...
Blog
The German Financial Stabilization of Statutory Health Insurance System Act
Executive Summary: Key Policy Updates AMNOG Rebate Negotiations AMNOG* rebate negotiations will be modified to give the GKV-SV increased powers in the pricing negotiations. HIGH P&MA IMPACT: The new negotiation framework increases the threshold of added benefit required for therapies...
Blog
Brazil’s Latest Updates to Drug Coverage in the Private Sector: Anticipated Impact and Implications
Executive Summary Introduction Agência Nacional de Saúde Suplementar (ANS) is the Brazilian regulatory agency linked to the Ministry of Health that oversees the private healthcare sector and insurance companies within the country. Key responsibilities of ANS include defining the legislation...
Blog
Japan’s Latest Drug Pricing Policy Updates: Key Changes in 2022 and the Expected Impact
A series of new drug pricing reforms came into effect in Japan in April 2022, to encourage innovation and ensure the transparency and predictability of drug pricing in the future. These include updates to the cost-accounting pricing methodology, an expansion of...
Blog
Inflation Reduction Act of 2022: No Room for Negotiation
Long-awaited Medicare price negotiations look more like statuary discounts than the value-based negotiations seen in global healthcare systems; combined with expanded price increase rebates and out of pocket limits, new regulation may drive prices for new drugs up more than down....
